Flavoxate HCI
Flavoxate HCI Brand names, Flavoxate HCI Analogs
Flavoxate HCI Brand Names Mixture
- No information avaliable
Flavoxate HCI Chemical_Formula
C58H73N7O17
Flavoxate HCI RX_link
No information avaliable
Flavoxate HCI fda sheet
Flavoxate HCI msds (material safety sheet)
Flavoxate HCI Synthesis Reference
No information avaliable
Flavoxate HCI Molecular Weight
1140.24 g/mol
Flavoxate HCI Melting Point
No information avaliable
Flavoxate HCI H2O Solubility
Practically insoluble
Flavoxate HCI State
Solid
Flavoxate HCI LogP
0.216
Flavoxate HCI Dosage Forms
Injection (50 mg vials to be reconstituted prior to injection)
Flavoxate HCI Indication
For use in the treatment of the following fungal infections: Candidemia and other forms of Candida infections (intra-abdominal abscess, and peritonitis) and esophageal candidiasis.
Flavoxate HCI Pharmacology
Anidulafungin is a semi-synthetic lipopeptide synthesized from a fermentation product of Aspergillus nidulans. Anidulafungin is an echinocandin, a class of antifungal drugs that inhibits the synthesis of 1,3-β-D-glucan, an essential component of fungal cell walls. Anidulafungin is active in vitro against Candida albicans, C. glabrata, C. parapsilosis, and C. tropicalis.
Flavoxate HCI Absorption
No information avaliable
Flavoxate HCI side effects and Toxicity
During clinical trials a single 400 mg dose of anidulafungin was inadvertently administered as a loading dose. No clinical adverse events were reported. The maximum non-lethal dose of anidulafungin in rats was 50 mg/kg, a dose which is equivalent to 10 times the recommended daily dose for esophageal candidiasis (50mg/day).
Flavoxate HCI Patient Information
Flavoxate HCI Organisms Affected
Aspergillis, Candida and other fungi
